Predictive impact of residual disease detected using multiparametric flow cytometry on risk stratification of paediatric acute myeloid leukaemia with normal karyotype

2021 ◽  
Author(s):  
Hui‐min Zeng ◽  
Guan‐hua Hu ◽  
Ai‐dong Lu ◽  
Yue‐ping Jia ◽  
Ying‐xi Zuo ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
Risk Stratification ◽  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Residual Disease ◽  
Normal Karyotype ◽  
Multiparametric Flow Cytometry ◽  
Acute Myeloid

Feasibility ofBAALCgene expression for detection of minimal residual disease and risk stratification in normal karyotype acute myeloid leukaemia

2016 ◽  
Vol 175 (5) ◽  
pp. 904-916 ◽  
Author(s):  
Simone Weber ◽  
Torsten Haferlach ◽  
Tamara Alpermann ◽  
Karolína Perglerová ◽  
Susanne Schnittger ◽  
...  
Keyword(s):  
Risk Stratification ◽  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
Normal Karyotype ◽  
Minimal Residual ◽  
Acute Myeloid

Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia

2016 ◽  
Vol 40 ◽  
pp. 1-9 ◽  
Author(s):  
María-Belén Vidriales ◽  
Estefanía Pérez-López ◽  
Carlota Pegenaute ◽  
Marta Castellanos ◽  
José-Juan Pérez ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
Treatment Decisions ◽  
Minimal Residual ◽  
Acute Myeloid

scholarly journals Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO-AML 2004 study

2016 ◽  
Vol 174 (4) ◽  
pp. 600-609 ◽  
Author(s):  
Anne Tierens ◽  
Elizabeth Bjørklund ◽  
Sanna Siitonen ◽  
Hanne Vibeke Marquart ◽  
Gitte Wulff -Juergensen ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Residual Disease ◽  
Independent Predictor ◽  
Acute Myeloid

scholarly journals Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype

2016 ◽  
Vol 50 (4) ◽  
pp. 385-393 ◽  
Author(s):  
Marijana Virijevic ◽  
Teodora Karan-Djurasevic ◽  
Irena Marjanovic ◽  
Natasa Tosic ◽  
Mirjana Mitrovic ◽  
...  
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
De Novo ◽  
Residual Disease ◽  
Disease Free Survival ◽  
Normal Karyotype ◽  
Isocitrate Dehydrogenase 1 ◽  
The Stability ◽  
Acute Myeloid

Abstract Background Mutations in the isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) genes are frequent molecular lesions in acute myeloid leukaemia with normal karyotype (AML-NK). The effects of IDH mutations on clinical features and treatment outcome in AML-NK have been widely investigated, but only a few studies monitored these mutations during follow-up. Patients and methods In our study samples from 110 adult de novo AML-NK were studied for the presence of IDH1 and IDH2 mutations, their associations with other prognostic markers and disease outcome. We also analyzed the stability of these mutations during the course of the disease in complete remission (CR) and relapse. Results IDH mutations were found in 25 (23%) patients. IDH+ patients tend to have lower CR rate compared to IDH-patients (44% vs 62.2%, p = 0.152), and had slightly lower disease free survival (12 months vs 17 months; p = 0.091). On the other hand, the presence of IDH mutations had significant impact on overall survival (2 vs 7 months; p = 0.039). The stability of IDH mutations were studied sequentially in 19 IDH+ patients. All of them lost the mutation in CR, and the same IDH mutations were detected in relapsed samples. Conclusions Our study shows that the presence of IDH mutations confer an adverse effect in AML-NK patients, which in combination with other molecular markers can lead to an improved risk stratification and better treatment. Also, IDH mutations are very stable during the course of the disease and can be potentially used as markers for minimal residual disease detection.

Aberrant Expression of CD Markers in Acute Myeloid Leukaemia

2018 ◽  
Vol 2 (01) ◽  
pp. 14-16
Author(s):  
Abul Kalam Azad ◽  
Md. Rafiquzzaman Khan ◽  
ABM Hasan Habib ◽  
Md. Abdul Wadud Miah ◽  
Masuda Begum
Keyword(s):  
Flow Cytometry ◽  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Acute Leukaemia ◽  
Antigen Expression ◽  
Aberrant Expression ◽  
Female Ratio ◽  
Cd Antigen ◽  
Cd Markers ◽  
Acute Myeloid

Background: Aberrant expression of cluster differentiation (CD) antigen marker is associated with poor outcome of acute leukaemia. Objective: Aim of this study is to determine the frequency and pattern of aberrant expression of CD markers in acute myeloid leukaemia patients in Bangladesh. Methods: This retrospective data analysis was conducted in the Department of Haematology, Bangabandhu Sheikh Mujib Medical University (BSMMU) to assess the frequency of aberrant CD antigen expression in acute myeloid leukaemia from October 2016 to September 2017. During this period, we did one hundred flow cytometry of acute leukaemia patients and among them we found 48 acute myeloid Leukaemia (AML) who were included in this study. Result: Mean age of patients was 35 years (SD­ +14 years; Rang 3 to 50 years) with male: female ratio of 0.92. Four colour flow cytometry was done on fresh bone marrow aspirates and peripheral blood. Among 48 AML patients, aberrant CD expression was observed in 58% cases.  CD5 and cCD79a lymphoid markers were seen to be expressed in 32% cases of AML. Aberrant cCD3 and CD7 were expressed in 29% and 25% cases respectively and aberrant CD10, CD19, cCD22 were expressed in 11%, 3%, 3% cases acute myeloid leukaemia patients respectively. Conclusion: Aberrant CD antigen expression is not uncommon in AML patients of Bangladeshi population that may adversely affect the treatment outcome of the disease.

Sign in / Sign up

Export Citation Format

Share Document